Immunotherapy Response and Clinical Outcomes in Autoimmune Encephalitis: a Systematic Review and Meta-analysis of First- and Second-line Therapies (P9-1.001)

June 9, 2026Neurology

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to evaluate how first-line and second-line immunotherapies differ in effectiveness for treating antibody-confirmed autoimmune encephalitis.
Conducted a systematic review and meta-analysis of existing studies.
Focused on the efficacy of first-line and second-line immunotherapy treatments.
Analyzed clinical outcomes related to antibody-confirmed autoimmune encephalitis.
Identified notable differences in outcomes between first-line and second-line immunotherapies.
First-line therapies showed superior efficacy compared to second-line treatments in several cases.
Clinical outcomes varied based on the type of immunotherapy utilized, highlighting differential responses.

Systematic review examines immunotherapy efficacy in autoimmune encephalitis, indicating potential treatment differences.

This study aims to examine the differential efficacy of first-line versus second-line immunotherapies in antibody-confirmed AE.

No takes yet. Share an insight, caveat, or question.

Ghadeer Jumah (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share